Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc.
Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked with OneThree to build a tailored AI approach that leverages Poolbeg’s RSV human challenge trial data to identify disease-relevant biological pathways and potential drug targets.
Based on those newly discovered drug targets, the collaboration has now identified promising drug candidates to bring forward to lab-based validation to determine the full potential of these assets.
Poolbeg has prioritized compounds with existing phase I clinical data and that could, if successfully validated, be repositioned as novel treatments for RSV infection. Candidates with solid safety and pharmacodynamic data in humans are well positioned to rapidly enter a clinical trial to generate early human efficacy data for RSV.
‘Tripledemic’
RSV, which inflames the smallest airways of the lungs, usually sends between 58,000 and 80,000 children under the age of five to hospital each year in the U.S. alone, according to the US Centers for Disease Control and Prevention (CDC).
RSV can also be dangerous for adults over the age of 65, resulting in around 177,000 hospitalizations per year in the U.S. The current cold and flu season commenced about two months earlier than anticipated and already rivals some of the worst seasons on record with RSV hospitalizing young children in the U.S. and Europe at an alarming rate. Public health officials have been warning a “tripledemic” of SARS-CoV-2, influenza and RSV would strain an already weary healthcare system.
Jeremy Skillington, CEO of Poolbeg Pharma said: “In the past few months, RSV has been sending children to hospital at alarming rates in the United States and Europe. As pediatric units fill beyond capacity, and our healthcare systems contend with a ‘tripledemic’ of RSV, influenza and SARS-CoV-2, the need for better treatments has never been so urgent.
“We’re impressed with the quality of work executed so far with OneThree leveraging their AI expertise to present new drug potential candidates from our unique human challenge trial data which Poolbeg will now optimize for further development in RSV, the only one of the three main respiratory illnesses for which there are not yet any approved vaccines and where treatment options are limited.”
Most vulnerable
Neel S. Madhukar, co-founder and CEO of OneThree Biotech, said: “We are very pleased to be working with Poolbeg and to have the opportunity to deploy the ATLANTIS platform to complete the first ever AI-driven analysis of RSV disease progression data.
“I am delighted that Poolbeg’s unique dataset combined with OneThree’s externally validated platform have now delivered new actionable insights surrounding disease biology and drug discovery that can bring much needed treatment options for both the young and the elderly; the most vulnerable to RSV infection.”
Are you interested in respiratory disease R&D?
